An open-label study of the effect of Tarceva [erlotinib] monotherapy on treatment response in patients with advanced non-small cell lung cancer for whom Tarceva monotherapy is considered the best option.
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2014
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Roche
- 22 Nov 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01996332)
- 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by Roche website.